Clinical Trials
18
Active:0
Completed:8
Trial Phases
3 Phases
Phase 1:4
Phase 2:10
Phase 3:3
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 2
10 (58.8%)Phase 1
4 (23.5%)Phase 3
3 (17.6%)A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
Phase 2
- Conditions
- Septic ShockCatecholamine-resistant Hypotension (CRH)Distributive ShockHigh Output Shock
- Interventions
- Drug: LJPC-501 (angiotensin II)Drug: Placebo
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 100
- Registration Number
- NCT03623529
- Locations
- 🇱🇹
Investigational Site, Vilnius, Lithuania
A Study of LJPC-501 in Pediatric Patients With Hypotension
Phase 2
Completed
- Conditions
- Catecholamine-resistant Hypotension (CRH)Distributive ShockHigh Output ShockSepsis
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 2
- Registration Number
- NCT03431077
- Locations
- 🇺🇸
Investigational Site, San Antonio, Texas, United States
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 70
- Registration Number
- NCT03395704
- Locations
- 🇬🇧
Investigative Site, Portsmouth, England, United Kingdom
🇺🇸Investigational Site, San Diego, California, United States
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 84
- Registration Number
- NCT03381833
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Expanded Access for LJPC-501
- Conditions
- Catecholamine Resistant Hypotension (CRH)Distributive ShockHigh Output ShockSepsisVasodilatory Shock
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT03245528
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found